{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T05:10:04Z","timestamp":1751087404683,"version":"3.41.0"},"reference-count":18,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.3960\/jslrt.25013","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T22:07:53Z","timestamp":1751062073000},"page":"101-106","source":"Crossref","is-referenced-by-count":0,"title":["Case series of long-term responders to pralatrexate in peripheral T-cell lymphoma"],"prefix":"10.3960","volume":"65","author":[{"given":"Naoto","family":"Tomita","sequence":"first","affiliation":[{"name":"Hematology and Oncology, St. Marianna University School of Medicine, Kanagawa, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Kitazume","sequence":"additional","affiliation":[{"name":"Department of Hematology, Showa General Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Kitajima","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saiseikai Niigata Hospital, Niigata, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Hayata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fukuchiyama City Hospital, Kyoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuku","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Hematology, Shonan Kamakura General Hospital, Kanagawa, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tokai University School of Medicine, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Swerdlow SH, Campo E, Pileri SA <i>et al.<\/i> The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127: 2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Kato K. Advances in Diagnosis and Treatment in Peripheral T-Cell Lymphoma. J Jpn Soc Int Med. 2021; 110: 1418-1425 [in Japanese].","DOI":"10.2169\/naika.110.1418"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Simon A, Peoch M, Casassus P <i>et al.<\/i> Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010; 151: 159-166.","DOI":"10.1111\/j.1365-2141.2010.08329.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Mak V, Hamm J, Chhanabhai M <i>et al.<\/i> Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013; 31: 1970-1976.","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Serova M, Bieche I, Sablin MP <i>et al.<\/i> Single agent and combination studies of pralatrexate and molecular correlates of sensitivity. Br J Cancer. 2011; 104: 272-280.","DOI":"10.1038\/sj.bjc.6606063"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 O\u2019Connor OA, Horwitz S, Hamlin P <i>et al.<\/i> Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009; 27: 4357-4364.","DOI":"10.1200\/JCO.2008.20.8470"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 O\u2019Connor OA, Pro B, Pinter-Brown L <i>et al.<\/i> Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011; 29: 1182-1189.","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Maruyama D, Nagai H, Maeda Y <i>et al.<\/i> Phase I\/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci. 2017; 108: 2061-2068.","DOI":"10.1111\/cas.13340"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Bellei M, Foss FM, Shustov AR <i>et al.<\/i> The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica. 2018; 103: 1191-1197.","DOI":"10.3324\/haematol.2017.186577"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Stuver RN, Khan N, Schwartz M <i>et al.<\/i> Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry. Am J Hematol. 2019; 94: 641-649.","DOI":"10.1002\/ajh.25463"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Ma H, Cheng B, Falchi L <i>et al.<\/i> Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials. Hematol Oncol. 2020; 38: 51-58.","DOI":"10.1002\/hon.2705"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Pro B, Advani R, Brice P <i>et al.<\/i> Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017; 130: 2709-2717.","DOI":"10.1182\/blood-2017-05-780049"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Ghione P, Faruque P, Mehta-Shah N <i>et al.<\/i> T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma. Blood Adv. 2020; 4: 4640-4647.","DOI":"10.1182\/bloodadvances.2020002396"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 O\u2019Connor OA, Marchi E, Volinn W <i>et al.<\/i> Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study. JNCI Cancer Spectr. 2018; 2: pky038.","DOI":"10.1093\/jncics\/pky038"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Amador C, Greiner TC, Heavican TB <i>et al.<\/i> Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. Blood. 2019; 134: 2159-2170.","DOI":"10.1182\/blood.2019000779"},{"key":"#cr-split#-16.1","doi-asserted-by":"crossref","unstructured":"16 Matutes E. The 2017 WHO update on mature T- and natural killer (NK) cell neoplasms. Int J Lab Hematol. 2018","DOI":"10.1111\/ijlh.12817"},{"key":"#cr-split#-16.2","unstructured":"16 Matutes E. The 2017 WHO update on mature T- and natural killer"},{"key":"#cr-split#-16.3","doi-asserted-by":"crossref","unstructured":"(NK) cell neoplasms. Int J Lab Hematol. 2018; 40: 97-103.","DOI":"10.1111\/ijlh.12817"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/2\/65_25013\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T04:45:35Z","timestamp":1751085935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/2\/65_25013\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25013","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"type":"print","value":"1346-4280"},{"type":"electronic","value":"1880-9952"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25013"}}